Table 1. Patient demographics and clinical parameters.
|
LN-ER/PR+Her2- status
|
LN+ER/PR-Her2+ status
|
|||
|---|---|---|---|---|
| Relapse | No relapse | Relapse | No relapse | |
| Number of patients | 12 | 81 | 39 | 51 |
| Age in year | 53.25±14.27 | 51.07±10.06 | 47.77±9.10 | 46.41±8.35 |
| Time to relapse (months) | 23.83±8.29 | - | 17.59±10.38 | - |
| Pre-/post-menopausal | 5/7 | 45/36 | 17/22 | 28/23 |
| Tumor size (mm) | 1.90±0.67 | 2.34±1.16 | 3.92±1.82 | 3.2±1.47 |
| Family carcinoma history +/- | 6/6 | 21/60 | 25/14 | 15/36 |
| Stage I/IIa/IIb/III | 8/2/2/0 | 46/29/6/0 | 6/14/9/10 | 17/23/7/4 |
| Her2+/++/+++ | - | - | 14/20/5 | 23/19/9 |
| ER content ≤30%/31%-60%/>60% | 3/4/5 | 12/34/35 | - | - |
| PR content ≤30%/31%-60%/>60% | 4/0/8 | 8/30/43 | - | - |
| PCNA content - / ≤30%/31%-60%/>60% | 1/1/2/8 | 7/7/27/40 | 0/3/23/13 | 6/7/23/15 |
| P53 content - / ≤30%/31%-60%/>60% | 8/3/1/0 | 59/12/2/1 | 15/0/7/17 | 25/1/12/13 |
| Lymph node <4/4-9/>9 | - | - | 16/13/10 | 34/12/5 |
| Radiation/no radiation | 12/0 | 81/0 | 39/0 | 51/0 |
| Adjuvant therapy: hormonal (tamoxifen) | 12/0 | 81/0 | 0/39 | 0/51 |